Entrada raises $59M series A to take intracellular biologic into clinic

Entrada Therapeutics Inc. (Boston, Mass.) emerged from stealth Tuesday after raising $59 million in a series A round intended to propel its first intracellular biologics program into clinic.

Intracellular targets have proven challenging for small molecules and antibodies alike; small molecules require a defined, hydrophobic binding pocket, and antibodies cannot cross the cell's lipid bilayer (see "Breaking the Barrier")...